Treatment of Acinetobacter spp. infections

Bibliography

• BERGOGNE-BÈR.EZIN E: The increasing significance of outbreaks of Acinetobacter spp: the need for control and new agents. J. Hosp. Infect. (1995) 30:441-452. An extensive review on the problem of Acinetobacter spp. infections and difficulties of treatment.
   Google Scholar
• WISPLINGHOFF H, EDMOND MB, PFALLER MA, JONES RN, WENZEL RP, SIEFERT H: Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin. Infect. Dis. (2000) 31:690–697.
   PubMed Web of Science ®Google Scholar
• LEVIN AS, MENDES CM, SINTO SI et al.: An outbreak of multiresistant Acinetobacter baumannii in a university hospital in Sao Paulo, Brazil. Infect. Control Hosp. Epidemiol (1996) 17:366–368.
   PubMedGoogle Scholar
• GARCIA-GARMENDIA JL, ORTIZ-LEYBA C, GARNACHO-MONTERO J et al.: Risk factors for Acinetobacter baumannii nosoromial bacteremia in critically ill patients: a cohort study. Clin. Infect. Dis. (2001) 33:939–946.
   PubMed Web of Science ®Google Scholar
• SANTUCCI SG, GOBARA S, SANTOS CR, FONTANA C, LEVIN AS: Infections in a burn intensive care unit: experience of seven years. J. Hosp. Infect. (2003) 53:6–13.
   PubMed Web of Science ®Google Scholar
• CORBELLA X, MONTERO A, PUJOL M et al.: Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. Clin. Microbial. (2000) 36:4086–4095.
   Google Scholar
• D'AGATA EM, THAYER V, SHAFFNER W: An outbreak of Acinetobacter baumannii: the importance of cross-transmission. Infect. Control Hosp. Epidemiol (2000) 21:588–591.
   PubMed Web of Science ®Google Scholar
• ONARHEIM H, HOIVIK T, HARTHUG S, DIGRANES A, MYLVAGANAM H, VINDENES HA: Outbreak of multiresistant Acinetobacter baumannii infection. Tidsskr: Nor. Laegeforen. (2000) 120:1028–1033.
   PubMedGoogle Scholar
• KAPPSTEIN I, GRUNDMANN H, HAUER T, NIEMEYER C: Aerators as a reservoir for Acinetobacter junii: an outbreak of bacteremia in paediatric oncology patients. J. Hosp. Infect. (2000) 44:27–30.
   PubMed Web of Science ®Google Scholar
• PODNOS YD, CINAT ME, WILSON SE, COOKE J, GORNICK W, THRUPP LD: Eradication of multi-drug resistant Acinetobacter from an intensive care unit. Surg. Infect. (2001) 2:297–301.
   PubMedGoogle Scholar
• MAH MW, MEMISH ZA, CUNNINGHAM G, BANNATYNE RM: Outbreak of Acinetobacter baumannii in an intensive care unit associated with tracheostomy. Americanj Hosp. Infect. (2001) 29:284–288.
   PubMed Web of Science ®Google Scholar
• ROBERTS SA, FINDLAY R, LANG SD: Investigation of an outbreak of multi-drug resistant Acinetobacter baumannii in an intensive care burns unit. I Hosp. Infect. (2001) 48:228–232.
   PubMed Web of Science ®Google Scholar
• LING ML, ANG A, WEE M, WANG GC: A nosocomial outbreak of multiresistant Acinetobacter baumannii originating from an intensive care unit. Infect. Control Hosp. Epidemia (2001) 22:48–49.
   PubMed Web of Science ®Google Scholar
• FIEROBE L, LUCET JC, DECRE D et al:An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect. Control Hosp. Epidemia (2001) 22:35–40.
   PubMedGoogle Scholar
• HUANG YC, SU LH, WU TL, LEU HS, HSIEH WS, CHANG TM, LIN TY: Outbreak of Acinetobacter baumannii bacteremia in a neonatal intensive care unit: clinical implications and genotyping analysis. Pediatr. Infecti. Dis. .1. (2002) 21:1105–1109.
   PubMedGoogle Scholar
• SALAS CORONAS J, CABEZAS FERNANDES T, ALVAREZ-OSSORIO GARCIA DE SORIA R, ROGADO GONZALEZ MC, DELGADO FERNANDEZ M, DIEZ GARCIA F: Nosocomial infection/colonization of the respiratory tract caused by Acinetobacter baumannii in an internal medicine ward. An. Med. Interim (2002) 19:511–514.
   PubMedGoogle Scholar
• AYGUN G, DEMIRKIRAN 0, UTKU T et al: Environmental contamination during a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. Hosp. Infect. (2002) 52:259–262.
   Google Scholar
• VAN DESSEL H, KAMP-HOPMANS TE, FLUIT AC et al: Outbreak of a susceptible strain of Acinetobacter species 13 (sensu Tjernberg and Ursing) in an adult neurosurgical intensive care unit. Hosp. Infect. (2002) 51:89–95.
   Google Scholar
• LEVIDIOTOU S, GALANAKIS E, VRIONI G, PAPAMICHAEL D, NAKOS G, STEFANOU D: A multi-resistant Acinetobacter baumannii outbreak in a general intensive care unit. In vivo (2002) 16:117–122.
   PubMedGoogle Scholar
• SIMOR AE, LEE M, VEARNCOMBE M et al: An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infect. Control Hosp. Epidemia (2002) 23:261–267.
   PubMed Web of Science ®Google Scholar
• DAS I, LAMBERT P, HILL D, NOY M, BION J, ELLIOTT T: Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units. J. Hosp. Infect. (2002) 50:110–114.
   PubMed Web of Science ®Google Scholar
• HANBERGER H, DIEKEMA D, FLUIT A et al: Surveillance of antibiotic resistance in European ICUs. I Hosp. Infect. (2001) 48:161–176.
   PubMed Web of Science ®Google Scholar
• ••An interesting and extensive review onresistance of different microorganisms to various antimicrobials over time in different parts of the world.
   Google Scholar
• KRAWCZYK B, LEWANDOWSKI K, KUR J: Comparative studies of the Acinetobacter genus and the species identification method based on the recA sequences. Ma Cell. Probes (2002) 16:1–11.
   PubMedGoogle Scholar
• BOUVET JM, GRIMONT PAD: Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii. Int. .1 Syst. Bacteria (1986) 36:228–240.
   Google Scholar
• TJENBERG I: Antimicrobial susceptibility of Acinetobacter strains identified by DNA-DNA hybridization. APMIS (1990) 98:320–326.
   PubMedGoogle Scholar
• GERNER-SMIDT P, FREDERIKSEN W: Acinetobacter in Denmark: I. Taxonomy, antibiotic susceptibiblity, and pathogenicity of 112 clinical isolates. APMIS (1993) 101:815–825.
   Google Scholar
• HOSTACKA A, KLOKOCNIKOVA L: Characteristics of clinical Acinetobacter spp. strains. Folia Microbia (Praha) (2002) 47:579–582.
   PubMedGoogle Scholar
• TRAUB WH, SPOHR M: Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrob. Agents Chemother: (1997) 33:1617–1619.
   Google Scholar
• HSUEH PR, LIU CY, LUH KT: Current status of antimicrobial resistance in Taiwan. Emerg. Infect. Dis. (2002) 8:132–137.
   PubMedGoogle Scholar
• JONES RN: Resistance patterns among nosocomial pathogens. trends over the past few years. Chest (2001) 119:397S–404S.
   Google Scholar
• MANIKAL VM, LANDMAN D, SAURINA G, OYDNA E, LAL H, QUALE J: Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin. Infect. Dis. (2000) 31:101–106.
   PubMed Web of Science ®Google Scholar
• GUZMAN-BLANCO M, CASELLAS JM,SADER HS: Bacterial resistance to antimicrobial agents in Latin America. Infect. Dis. Clin. North Am. (2000) 14:67–81.
   PubMedGoogle Scholar
• SADER HS, GALES AC, PFALLER MA et al.: Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Brazilianj Infect. Dis. (2001) 5:200–214.
   PubMedGoogle Scholar
• HSUEH PR, TENG LJ, CHEN CY et al: Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg. Infect. Dis. (2002) 8:827–832.
   PubMed Web of Science ®Google Scholar
• LANDMAN DJ, QUALE JM, MAYORCA D et al.: Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklin, NJ. The preantibiotic era has returned. Arch. Intern. Med. (2002) 162:1515–1520.
   PubMedGoogle Scholar
• LEVIN AS: M multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin. Microbia Infect. (2002) 8:144–153.
   PubMed Web of Science ®Google Scholar
• •A review of the literature on treatment of Acinetobacter spp. infections with sulbactarn.
   Google Scholar
• CATCHPOLE CR, ANDREWS JM, BRENWALD N, WISE R: A reassessment of the in vitro activity of colistin sulphomethate sodium. I. Antimicrob. Chemother: (1997) 39:255–260.
   PubMed Web of Science ®Google Scholar
• HORTON J, PANKEY GA: Polymyxin B, colistin, and sodium colistimethate. Med. Clio. North Am. (1982) 66:135–142.
   PubMed Web of Science ®Google Scholar
• ••A very comprehensive review of clinicaland pharmacological aspects of the polymyxins.
   Google Scholar
• GALES AC, REIS AO, JONES RN: Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Chn. Microbial. (2001) 39:183–190.
   PubMed Web of Science ®Google Scholar
• •Addresses the problems with susceptibility testing for polymyxins and suggests criteria for interpretation.
   Google Scholar
• ACAR JF: Antibiotic synergy and antagonism. Med. Clio. North Am. (2000) 84:1391–1406.
   PubMed Web of Science ®Google Scholar
• JOLY-GUILLOU ML, DECRE D, HERRMAN JL, BOURDELIER E, BERGOGNE-BEREZIN E: Bactericidal in-vitro activity of P-lactams and I3-lactamase inhibitors, alone or associated, against strains of Acinetobacter baumannii: effect of combination with aminoglycosides. Antimicrob. Chernother. (1995) 36:619–629.
   PubMed Web of Science ®Google Scholar
• MARQUES MB, BROOKINGS ES, MOSER SA, SONKE PB, WAITES KN: Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicreb. Agents Chemether. (1997) 41:881–885.
   PubMed Web of Science ®Google Scholar
• SAVOV E, CHANKOVA D, VATCHEVA R, DINEV N: In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin-sulbactam alone and in combination with amikacin. Int. I Antimicreb. Agents (2002) 20:390–392.
   PubMed Web of Science ®Google Scholar
• MONTERO A, ARIZA J, CORBELLA X,DOMENECH A et al: Efficacy of colistin versus I3-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicreb. Agents Chemether. (2002) 46:1946–1952.
   PubMed Web of Science ®Google Scholar
• WOLFF M, JOLY-GUILLOU ML, FARINOTTI R, CARBON C: In vivo efficacies of combinations of I3-lactams, I3-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicreb. Agents Chemether. (1999) 43:1406–1411.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-HERNANDEZ MJ, PACHON J, PICHARDO C et al.: Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. Antimicreb. Chemether. (2000) 45:493–501.
   PubMedGoogle Scholar
• RODRIGUEZ-HERNANDEZ MJ, CUBEROS L, PICHARDO C et al: Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. .1. Antimicreb. Chemethec (2001) 47:479–482.
   PubMed Web of Science ®Google Scholar
• KULHANJIAN J, DUNPHY MG, HAMSTRA S et al.: Randomized comparative study of ampicillin/sulbactam versus ceftriaxone for treatment of soft tissue and skeletal infections in children. Pediatr. Infect. Dis. J. (1989) 8:605–610.
   PubMedGoogle Scholar
• GENTRY LO, RODRIGUEZ-GOMEZ G, ZELUFF BJ, KHOSHEDEL A, PRICE M: A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am. J. Med. (1989) 87:57S–60S.
   Google Scholar
• GENTRY LO, RODRIGUEZ-GOMEZ G: Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicreb. Agents Chemether. (1991) 35:538–541.
   PubMed Web of Science ®Google Scholar
• TORRES A, DE CELIS R, RABINAD E et al.: Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. comparative study against amikacin combined with cefotaxime. Chemotherapy (1989) 35:15–24.
   Google Scholar
• RAPP RP, BILLETER M, HATTON J, YOUNG AB, TIBBS PA, DEMPSEY RJ: Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. Clio. Pharm. (1991) 10:49–55.
   PubMedGoogle Scholar
• GUCEK A, BREN AF, LINDIC J, HERGOUTH V, MLINSEK D: Is monotherapy with cefazolin or ofloxacin an adequate treatment for peritonitis in CAPD patients? Adv. Pent. Dial. (1994) 10:144–146.
   PubMedGoogle Scholar
• SIEBERT WT, KOPP PE: Ticarcillin plusclavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections. Am. I Med. (1985) 79:141–145.
   Google Scholar
• GIAMARELLOU H, MANDRAGOS K, BECKRAKIS P, PIGAS K, BILALIS D, SFIKAKIS P: Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients. Antimicreb. Chemethec (1990) 26:117–127.
   PubMedGoogle Scholar
• WOOD GC, HANES SD, CROCE MA, FABIAN TC, BOUCHER BA: Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clio. Infect. Dis. (2002) 34:1425–1430.
   PubMed Web of Science ®Google Scholar
• JELLISON TK, MCKINNON PS, RYBAK MJ: Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacetherapy (2001) 21:142–148.
   PubMed Web of Science ®Google Scholar
• GARNACHO-MONTERO J, ORTIZ-LEYBA C, JIMENEZ-JIMENEZ FJ et al.: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Chn. Infect. Dis. (2003) 36:1111–1118.
   PubMed Web of Science ®Google Scholar
• CISNEROS JM, REYES MJ, PACHON J et al: Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Chn. Infect. Dis. (1996) 22:1026–1032.
   PubMed Web of Science ®Google Scholar
• LEVIN AS, LEVY CE, MANRIQUE AEI, MEDEIROS ES, COSTA SF: Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin-sulbactam. Int. J. Antimicreb. Agents (2003) 21:58–62.
   PubMed Web of Science ®Google Scholar
• CAWLEY MJ, SUH C, LEES, ACKERMAN BH: Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacetherapy (2002) 22:527–532.
   PubMed Web of Science ®Google Scholar
• CORBELLA X, ARIZA J, ARDANUY C et al: Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. Antimicreb. Chemethec (1998) 42:793–802.
   PubMed Web of Science ®Google Scholar
• ••This study uses sulbactarn alone to treatAcinetobacter infections with good results and suggests that it is the active drug in the combination with arnpicillin.
   Google Scholar
• JIMENEZ-MEJTAS ME, PACHON J, BECERRIL B et al.: Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin-sulbactam. Clio. Infect. Dis. (1997) 24:932–935.
   PubMedGoogle Scholar
• FOULDS G: Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect. Dis. (1986) 8:S503–511.
   PubMedGoogle Scholar
• URBAN C, GO E, MARIANO N et al: Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus.J. Infect. Dis. (1993) 167:448–451.
   PubMed Web of Science ®Google Scholar
• TELENSI ASENSIO M, MORENO TORRICO A, RUIZ PALOMAR J, BERNALDO DE QUIROS JF: The efficacy of sulbactam-ampicillin in a urinary infection due to Acinetobacter calcoaceticus var. anitratus. Med. Clin. (Barcelona) (1995) 105:438–439.
   PubMedGoogle Scholar
• LEVIN AS, BARONE AA, PENCO J, SANTOS MV, MARINHO IS, MANRIQUE El, COSTA SF: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. (1999) 28:1008–1011.
   PubMed Web of Science ®Google Scholar
• ••A total of 60 cases of infection caused byimipenem-resistant Acinetobacterspp. and Pseudomonas aeruginosa are treated with colistin. Reports the largest recent experience with this drug.
   Google Scholar
• JIMENEZ-MEJTAS ME, PICHARDO-GUERRERO C, MARQUEZ-RIVAS FJ, MARTIN-LOZANO D, PRADOS T, PACHON J: Cerebrospinal fluid penetration and pharmacolkinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. Microbiol Infect. Dis. (2002) 21:212–214.
   PubMedGoogle Scholar
• MARSDEN HB, HYDE WA: Colistin methane sulphonate in childhood infections. Lancet (1962) 2:740–742.
   Google Scholar
• FERNANDEZ-VILADRICH P, CORBELLA X, CORRAL L, TUBAU F, MATEU A: Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter bauamannii with intraventricular colistin sulfomethate sodium. Clin. Infect. Dis. (1999) 28:916–917.
   PubMed Web of Science ®Google Scholar
• COLLARD HR, SAINT S, MATTHAY MA: Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Ann. Intern. Med. (2003) 138:494–501.
   PubMed Web of Science ®Google Scholar
• KOLLEF MH: Selective digestive decontamination should not be routinely employed. Chest (2003) 123:464S–468S.
   Google Scholar
• CHOTIGEAT U, KHORANA M, WARANAWAT N: Successful treatment of late onset infection due to multi-drug resistant Acinetobacter lwoffii in a low birth weight neonate using ciprofloxacin. Med. Assoc. Thai. (2001) 84:910–913.
   PubMedGoogle Scholar
• RAHAL JJ, URBAN C, SEGAL-MAURER S: Nosocomial antibiotic resistance in multiple Gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin. Infect. Dis. (2002) 34:499–503.
   PubMed Web of Science ®Google Scholar